Why BGPT?
logo

Review Papers Claim by Claim

Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.

Press Enter ↡ to start review



    Explore by Goal












     Quick Explanation


    BGPT take
    In this study, RNAi-mediated loss of FUS/TLS in NSC-34 (mouse) and HEK-293T (human) cells causes a dose/time-dependent proliferation defect accompanied by a strong mitotic-arrest signature (phospho-histone H3; p-H3) without overt apoptosis markers.
    The phenotype is reversible by FUS re-expression and is partially rescued by the PDE4 inhibitor rolipram, while TMT-based quantitative proteomics identifies coordinated proteome changes spanning cell-cycle/chromatin, energy homeostasis, cytoskeleton, and stress-related programs.
    Evidence source:



     Long Explanation


    Paper visual review (skeptical, evidence-first)
    Target paper: A loss of FUS/TLS function leads to impaired cellular proliferation ().
    What the paper claims (as testable statements)
    • FUS/TLS knockdown reduces proliferation/viability in NSC-34 and HEK-293T, with magnitude depending on knockdown efficiency and induction/transfection context.
    • Apoptosis is not the primary driver: cleaved PARP1/caspase-3 remain low/unchanged and AIF does not show nuclear translocation during the FUS knockdown time course.
    • Mitotic arrest is implicated: p-H3 signal increases strongly; ~45% p-H3+ at 96 h in shFUS conditions, comparable to nocodazole-treated cells.
    • Reversibility / rescue: growth defects are reversible upon washout (FUS levels return to baseline) and partially rescued by rolipram; rolipram does not restore FUS protein levels.
    • Proteomics links FUS depletion to pathway programs: TMT LC-MS/MS quantifies 2355 proteins; 61 pass differential criteria; hits include known FUS RNA-binding targets and pathway categories relevant to proliferation, chromatin organization, oxidative stress/energy homeostasis, cytoskeleton, and ion binding; EWS and MT2 increase, S100A6 decreases; histones show a 24 h decrease with recovery by 96 h.
    Visuals first: key reported magnitudes
    Figure A β€” Knockdown efficiency vs viability effect (reported)
    Figure B β€” Proliferation disruption metrics (reported)
    Notes: EdU incorporation is described as ~50% reduction after 96 h; p-H3 positive cells are reported as ~45% in shFUS at 96 h and compared to nocodazole.
    Figure C β€” Selected proteomics validation directionality (reported)
    Directionality encoded from the paper’s reported validation: S100A6 decreases; MT2 increases; EWS increases; histones decrease at 24 h and recover by 96 h.
    Mechanistic interpretation (what is known vs inferred)
    Most supported chain (high confidence)
    1. Known from this paper: Reducing FUS/TLS via shRNA/siRNA leads to decreased cell number/viability and reduced EdU incorporation.
    2. Known from this paper: Apoptosis markers are not strongly activated (cleaved PARP1/caspase-3 low/unchanged; AIF nuclear translocation absent under knockdown), suggesting proliferation/mitosis disruption rather than acute apoptosis.
    3. Known from this paper: Mitotic arrest signature rises (p-H3 comparable to nocodazole), aligning with impaired mitosis progression as a cause of reduced proliferation.
    4. Known from this paper: The phenotype is reversible by FUS re-expression/washout; this supports causality of FUS depletion (rather than irreversible damage or permanent off-target toxicity).
    Where the paper is more inferential (medium confidence)
    • The proteomics categories (chromatin organization, kinases/phosphatases, cytoskeleton, energy/cation/metal binding) are suggestive of pathways involved in the proliferation defect, but the paper does not (in the provided text) establish direct causal links from each proteomic change to mitotic arrest.
    • Rolipram partial rescue is interpreted as support for a stress/oxidative-stress component; however, rolipram is pleiotropic (as described in the paper), so rescue does not uniquely identify the proximate pathway.
    Critical review: limitations & blind spots (from within the paper)
    • Cell model generalization: The core experimental evidence uses NSC-34 and HEK-293T lines; these are informative but do not fully substitute for primary neuronal/glial contexts in vivo. (This is consistent with the paper’s own disease-context framing, but the causal mechanistic steps are still model-limited.)
    • Knockdown/off-target risk: RNAi induction/transfection can alter metabolism/proliferation independent of target; the paper includes controls (scrambled shRNA; uninduced proteomics control), but transient siRNA efficiency differed by model, and efficacy differences complicate quantitative comparisons across methods.
    • Thresholding & functional assignment: Proteomic hit calling uses fold-change and p-value filters plus grouping/annotation steps; these choices can change which proteins land in β€œhits,” and functional categorization partly depends on existing knowledge bases (DAVID/manual UniProt/NCBI/GeneCards referencing).
    • Mechanism not fully closed-loop: The paper shows reversibility and partial pharmacologic rescue, but it does not (in the provided excerpt) establish that individual proteomic candidates (e.g., MT2, S100A6, EWS) are necessary and sufficient to drive p-H3 mitotic arrest.
    Directed logic map (what connects to what)
    Nodes are grounded in the paper’s described experiments; edges reflect the claimed directionality.
    Grounding: all node/edge elements correspond to the paper’s experimental readouts and rescue/proteomics results summarized above.


    Feedback:    

    Updated: April 16, 2026

     BGPT Paper Review


    Study Novelty

    80%

    Novelty is primarily the breadth of the reported phenotype (mitotic-arrest-centered proliferation impairment) coupled with quantitative TMT proteomics across timepoints and reversibility/rescue experiments tied to FUS depletion in two cell contexts.


    Scientific Quality

    70%

    Scientific quality is strengthened by multi-assay phenotyping, reversibility experiments, inclusion of uninduced controls in proteomics, and proteomics validation. Main limitations are causal closure for individual proteomic candidates and model-generalization uncertainty.


    Study Generality

    70%

    The proliferation/mitosis phenotype of FUS depletion in cultured cells is general as a cellular homeostasis principle, but disease-relevant generality (e.g., neurons/glia in vivo) is not established within the provided study scope.


    Study Usefulness

    80%

    Useful for generating testable hypotheses: FUS depletion β†’ mitotic arrest-like phenotype; proteome changes nominate pathways (chromatin/energy/cytoskeleton/ions; EWS/MT2/S100A6/histone dynamics) for deeper mechanistic testing.


    Study Reproducibility

    70%

    Methods are relatively detailed (RNAi induction/knockdown context, MTT/EdU/p-H3/flow assays, TMT proteomics pipeline described with thresholds). Reproducibility may still vary due to cell-line handling and knockdown efficiency differences across transfection methods.


    Explanatory Depth

    70%

    It offers a fairly mechanistic *level* (mitotic arrest signature + proteome-associated pathways) but not full mechanistic causality for the mitosis phenotype and not a closed transcription-to-mitosis causal circuit.


    🎁 Authors: Collect 307 Free Science Tokens (β‰ˆ $30.7 USD)

    Claim My Author Tokens

    Use for 76 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $30.7 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    It parses the paper’s reported numeric readouts (knockdown %, viability %, EdU %, p-H3 %) into a structured table, then generates Plotly summary plots and a candidate-protein directionality chart from validated hits.



     Hypothesis Graveyard


    β€œFUS loss mainly triggers apoptosis, and p-H3 rises secondarily.” This is weakened because the paper reports low/unchanged cleaved PARP1/caspase-3 and no AIF nuclear translocation during the knockdown time course.


    β€œRolipram rescues primarily by restoring FUS expression.” This is weakened because the paper reports rolipram does not re-express FUS (western blot remains knocked down) even though proliferation improves partially.

     Science Art


    Paper Review: A loss of FUS/TLS function leads to impaired cellular proliferation Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending